ProShare Advisors
NRIX icon

ProShare Advisors’s Nurix Therapeutics NRIX Stock Holding History

ProShare Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Sell
15,941
-3,400
-18% -$57.9K ﹤0.01% 1263
2026
Q1 		$300K Sell
19,341
-3,453
-15% -$57.3K ﹤0.01% 1342
2025
Q4 		$432K Buy
22,794
+7,180
+46% +$103K ﹤0.01% 1217
2025
Q3 		$144K Sell
15,614
-2,691
-15% -$27.9K ﹤0.01% 1778
2025
Q2 		$208K Sell
18,305
-1,401
-7% -$15.1K ﹤0.01% 1701
2025
Q1 		$234K Sell
19,706
-3,426
-15% -$57.3K ﹤0.01% 1579
2024
Q4 		$436K Buy
23,132
+7,261
+46% +$166K ﹤0.01% 1361
2024
Q3 		$357K Buy
15,871
+5,834
+58% +$132K ﹤0.01% 1346
2024
Q2 		$209K Sell
10,037
-1,941
-16% -$30.2K ﹤0.01% 1511
2024
Q1 		$176K Buy
11,978
+998
+9% +$10.7K ﹤0.01% 1703
2023
Q4 		$113K Buy
+10,980
New +$75.3K ﹤0.01% 1760
2022
Q2 		– Sell
-10,489
Closed -$148K – 2009
2022
Q1 		$148K Sell
10,489
-2,639
-20% -$46.8K ﹤0.01% 1956
2021
Q4 		$380K Sell
13,128
-377
-3% -$11.4K ﹤0.01% 1637
2021
Q3 		$405K Sell
13,505
-2,589
-16% -$79.9K ﹤0.01% 1337
2021
Q2 		$427K Buy
16,094
+4,265
+36% +$125K ﹤0.01% 1642
2021
Q1 		$368K Buy
11,829
+3,249
+38% +$123K ﹤0.01% 1671
2020
Q4 		$282K Buy
+8,580
New +$284K ﹤0.01% 1654

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's NRIX Position: Q2 2026 in Review

ProShare Advisors reduced its Nurix Therapeutics (NRIX) stake by 18% in Q2 2026, selling an estimated $57.9K and leaving 15,941 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

ProShare Advisors first reported a position in NRIX in Q4 2020 and has held it in 17 quarters since. The position peaked at $436K in Q4 2024. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • ProShare Advisors held 15,941 shares of Nurix Therapeutics worth $387K as of Q2 2026.
  • ProShare Advisors sold 3,400 Nurix Therapeutics shares in Q2 2026, an estimated $57.9K.
  • Nurix Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1263 holding.
  • ProShare Advisors first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 17 quarters since.
  • ProShare Advisors's Nurix Therapeutics position peaked at $436K in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.